Actualités en direct des projets (non traduites)

Détails

...365020 times

Source

Création : 19 juillet 2022

Détails

On 19 June 2022, 04:26:15 UTC, PrimeGrid’s Sierpinski/Riesel Base 5 Problem project eliminated k=63838 by finding the mega prime: 63838*5^3887851-1 The prime is 2,717,497 digits long and enters Chris Caldwell's “The Largest Known Primes Database” ranked 99th overall. 58 k’s now remain in the Riesel Base 5 problem. The discovery was made by Scott Lee (freestman) of China using an AMD Ryzen 5 2600X Six-Core Processor with 32GB RAM, running Microsoft Windows 11 Professional x64 Edition. This computer took about 4 hours, 34 minutes to complete the prp test using LLR2. Scott is a member of the team, Chinese Dream. The prime was verified on 19 June 2022, 22:29 UTC, by an Intel(R) Core(TM) i3-9100F CPU @ 3.60GHz with 16GB RAM, running Linux. This computer took about 11 hours and 57 minutes to complete the primality test using LLR2. For more details, please see the official announcement.

Source

Création : 18 juillet 2022

Détails

The fifth challenge of the 2022 Series will be a 3-day challenge celebrating the day that our arbitrary measurement units for the Earth's rotation align to numerically resemble the fraction 22/7, which approximates the value of the infamous circle constant 'pi' with an error of 400ppm! Honestly, I'm not sure why March 14th gets all the love -- 3.14 is a much worse approximation for pi! The challenge will be offered on the PPS-LLR application, beginning 22 July 22:00 UTC and ending 25 July 22:00 UTC. To participate in the Challenge, please select only the Proth Prime Search LLR (PPS) project in your PrimeGrid preferences section. For more info, questions, and lively debate about the best approximation for pi (it's 3 😁), check out the forum thread for this challenge: https://www.primegrid.com/forum_thread.php?id=9959&nowrap=true#156359 Happy 22/7!

Source

Création : 17 juillet 2022

Détails

Discusses current errors with our BOINC platform and what is currently being fixed

Source

Création : 13 juillet 2022

Détails

Aliquot sequence 22^67 has terminated!!!



Source

Création : 12 juillet 2022

Détails

The IPD is excited to announce it's first designed protein medicine with full approval abroad.

Congrats and thank you to all Rosetta@home contributors! The computing you have provided has greatly aided in de novo protein design challenges such as vaccine development leading to breakthroughs like this.

For more information you can visit the IPD vaccine news post.

A video is also available here.


From the IPD news site:

• Clinical testing found the vaccine outperforms Oxford/AstraZeneca’s

• The protein-based vaccine, now called SKYCovione, does not require deep freezing

• University of Washington to waive royalty fees for the duration of the pandemic

• South Korea to purchase 10 million doses for domestic use

A vaccine for COVID-19 developed at the University of Washington School of Medicine has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older. The vaccine, now known as SKYCovione, was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria.

SK bioscience, the company leading the SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute COVID-19 vaccines around the world. In addition, the South Korean government has agreed to purchase 10 million doses for domestic use.

The Seattle scientists behind the new vaccine sought to create a ‘second-generation’ COVID-19 vaccine that is safe, effective at low doses, simple to manufacture, and stable without deep freezing. These attributes could enable vaccination at a global scale by reaching people in areas where medical, transportation, and storage resources are limited.

“We know more than two billion people worldwide have not received a single dose of vaccine,” said David Veesler, associate professor of biochemistry at UW School of Medicine and co-developer of the vaccine. “If our vaccine is distributed through COVAX, it will allow it to reach people who need access.”

The University of Washington is licensing the vaccine technology royalty-free for the duration of the pandemic.

Congrats and thank you again to all R@h contributors!

Source

Création : 6 juillet 2022